Expression of P-glycoprotein and p53 Protein in Stage IV Hepatocellular Carcinoma Treated with Systemic Chemotherapy.
- Author:
Sang Hyung CHO
1
;
Hyun Ho CHO
;
Young Ho KIM
;
Jinmo CHUNG
;
Daehyun CHOI
;
Kwanghee CHO
;
Jin Hyuk LEE
;
Sook Hyang JEONG
;
Chul Ju HAN
;
You Cheoul KIM
;
Jhin Oh LEE
;
Jin Haeng CHUNG
;
Seung Sook LEE
Author Information
1. Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea. jsh@kcchsun.kcch.re.kr
- Publication Type:Original Article
- Keywords:
Chemotherapy;
Neoplasplasm/Liver/Hepatocellular carcinoma;
P-glycoprotein;
p53 protein
- MeSH:
Biopsy, Fine-Needle;
Carcinoma, Hepatocellular*;
Drug Resistance;
Drug Therapy*;
Humans;
P-Glycoprotein*
- From:The Korean Journal of Hepatology
2001;7(4):459-466
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is a drug-resistant tumor. The expression of a multidrug resistant gene, P-glycoprotein (P-gp) is a major mechanism of drug resistance. The aims of our study were, firstly, to observe the expression rate of P-gp in HCC tissue obtained by percutaneous fine needle aspiration (PCNA) from stage IV HCC patients; secondly to examine the association between P-gp and chemotherapeutic response; and finally to investigate the correlation between p53 protein expression and P-gp expression. Subjects and METHODS: We studied 29 cases of stage IV HCC treated by systemic chemotherapy. Expression of P-gp and p53 were evaluated by immunohistochemical staining of HCC tissue with human monoclonal antibody, JSB-1 (Anti P-gp) and DO-7 (Anti p53), respectively. We analyzed the results of immunohistochemical staining of HCC tissues of the patients in relation to chemotherapeutic response and other clinical characteristics. RESULTS: The expression rate of P-gp was 27.6%. Partial response to anti-cancer chemotherapy was observed in 16.7% of the patients. Although we could not see a statistically significant association between P-gp expression and chemotherapeutic response, none of the responsive patients showed P-gp expression. p53 protein expression was found in 45% of the patients. There was no significant correlation between p53 protein expression and P-gp expression. CONCLUSIONS: Although the number of our study subjects was small, chemotherapy- responsive patients didn't show P-gp expression. P-gp expression might be used as a predictor of response to potentially toxic anti-cancer chemotherapy in HCC patients. Further study is warranted to confirm our results.
